Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

Bronchiolitis Obliterans Clinical Trial

Official title:

A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04239989
• Other study ID #: 2018-0489
• Secondary ID: NCI-2019-0825220
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 8, 2021
• Est. completion date: May 31, 2024

Study information

• Verified date: April 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Description:

PRIMARY OBJECTIVE: I. To assess the safety of itacitinib in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT). SECONDARY OBJECTIVES: I. To assess treatment failure at 3 months and 6 months. II. To assess change in symptom-based lung score at 3 months and 6 months. III. To assess change in the St. George Respiratory Questionnaire and Study Short Form 36 at 3 months and 6 months. IV. To assess change in the Lee chronic graft versus host disease (GVHD) symptom scale at 3 months and 6 months post-treatment. V. To assess change in 6-minute walk test at 3 months and 6 months. VI. To assess failure-free survival at 6 months. VII. To assess non-relapse mortality at 6 months. VIII. To assess overall survival at 6 months. OUTLINE: Patents receive itacitinib orally (PO) once daily (QD) for up to 1 year in the absence of disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 8
• Est. completion date: May 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

1. BOS diagnosed within the past 6 months of enrollment, defined by 2015 National Institutes of Health (NIH) Consensus Criteria 126

2. Age 18-75 years

3. Undergone allogeneic SCT

4. ANC >1,000/µL, hemoglobin > 8 gm/dL (untransfused) and platelet count >25,000/ µL (untransfused)

5. Karnofsky performance score >60

6. The ability to understand and sign a written informed consent form

7. Contraception for women and men of child bearing potential. Permitted methods should be at least 99% effective in preventing pregnancy.

8. Male patients must be willing to refrain from donating sperm during their participation in the study and for at least 3 months after completing the study.

Exclusion Criteria:

1. Prior treatment with any other JAK inhibitor (including Ruxolitinib) for BOS or any other indication within the past 6 months of enrolment.

2. Patients on mechanical ventilation or resting by pulse oximetry O2 saturation <88%

3. FEV1 <40% predicted

4. Relapsed primary malignancy for which SCT was performed

5. History of progressive multifocal leuko-encephalopathy (PML)

6. Active uncontrolled bacterial, fungal, parasitic, or viral infection

7. Known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections.

8. History of tuberculosis anytime after SCT

9. Severe renal dysfunction defined by serum creatinine > 2 mg/dL, creatinine clearance <60 mL/minute or dialysis dependence

10. Serum transaminases > 5 × upper limit of normal

11. inability to perform PFT reliably

12. Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.

13. Lactating/nursing women

14. Life expectancy < 6 months

15. Other severe organ dysfunction unrelated to underlying GVHD. For example, uncontrolled or significant cardiac disease, including any of the following: recent myocardial infarction (within last 6 months from randomization); New York Heart Association Class III or IV congestive heart failure; unstable angina (within last 6 months prior to randomization); clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular; tachycardia, and clinically significant second or third degree AV block without a pacemaker); uncontrolled hypertension. Or any other concurrent severe and/or uncontrolled medical conditions which, in the opinion of the investigator, could compromise participation in the study, pose a significant risk to the subject, or interfere with study results.

Related Conditions & MeSH terms

• Bronchiolitis
• Bronchiolitis Obliterans
• Bronchiolitis Obliterans Syndrome

Intervention

Drug:
• Itacitinib
Given PO
• Itacitinib Adipate
Given PO

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monitoring the Dose Limiting Toxicities (DLT) of administering Itacitinib	Number of participants who develop DLT's after the administration of the study drug	Up to 6 months
Secondary	Treatment failure	Defined as a decrease in the absolute value of % forced expiratory volume in 1 second (FEV1) by 10% or more.	At 3 and 6 months
Secondary	Changes in National Institutes of Health (NIH) symptom-based lung score	Improvement in NIH symptom-based lung score; Score 0 (no symptoms), Score 1 (shortness of breath with stairs), Score 2 (shortness of breath on flat ground), and Score 3 (shortness of breath at rest or requiring oxygen	At 3 and 6 months
Secondary	Change in well-established patient reported outcomes used in chronic graft versus host disease (GVHD) studies	Will include the St. George's Respiratory Questionnaire (SGRQ Regression models will include time, and different covariance structures will be included, including unstructured and autoregressive integrated moving average (ARIMA). The analysis will be adjusted for potential confounding variables. Participants will answer a St. George's Respiratory Questionnaire. (Very Poor, Poor, Fair, Good, Very Good)?	Baseline and at 3 and 6 months
Secondary	Change in well-established patient reported outcomes used in chronic graft versus host disease (GVHD) studies	Will include the Lee chronic GVHD symptom scale Lee symptom scale. Regression models will include time, and different covariance structures will be included, including unstructured and autoregressive integrated moving average (ARIMA). The analysis will be adjusted for potential confounding variables. The Lee Chronic GVHD Symptom Scale is a 30 item instrument with 7 subscales (skin, eyes, mouth, lung, nutrition, energy and psych) containing 2-7 items. Response options range from 0-4 (0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely).	Baseline up to 6 months
Secondary	Change in well-established patient reported outcomes used in chronic graft versus host disease (GVHD) studies	Will include the study Short Form 36 (SF-36), NIH lung symptom score and SF-36 due to the longitudinal nature of the observations. Regression models will include time, and different covariance structures will be included, including unstructured and autoregressive integrated moving average (ARIMA). The analysis will be adjusted for potential confounding variables.	Baseline and at 3 and 6 months
Secondary	Change in 6-minute walk test		Baseline and at 3 and 6 months
Secondary	Failure-free survival	Will be assessed and monitored	At 6 months
Secondary	Non-relapse mortality	Defined as the absence of need for additional line treatment, non-relapse mortality and recurrent malignancy.	At 6 months
Secondary	Overall survival	Will be assessed and monitored	At 6 months

External Links

•   MD Anderson Cancer Center